The cost of Alzheimer's disease in China and re-estimation of costs worldwide

@article{Jia2018TheCO,
  title={The cost of Alzheimer's disease in China and re-estimation of costs worldwide},
  author={J. Jia and Cuibai Wei and Shuoqi Chen and Fangyu Li and Yi Tang and W. Qin and Lina Zhao and Hongmei Jin and Hui Xu and Fen Wang and A. Zhou and X. Zuo and Liyong Wu and Ying Han and Yue Han and Liyuan Huang and Qi Wang and Dan Li and Changbiao Chu and Lu Shi and Min Gong and Yifeng Du and Jiewen Zhang and Junjian Zhang and Chunkui Zhou and Jihui Lv and Yang Lv and Haiqun Xie and Y. Ji and Fang Li and Enyan Yu and B. Luo and Yanjiang Wang and S. Yang and Q. Qu and Qihao Guo and Fu-ru Liang and Jintao Zhang and L. Tan and Lu Shen and Kunnan Zhang and Jinbiao Zhang and D. Peng and M. Tang and Peiyuan Lv and Bo Fang and Lan Chu and L. Jia and S. Gauthier},
  journal={Alzheimer's \& Dementia},
  year={2018},
  volume={14},
  pages={483-491}
}
The socioeconomic costs of Alzheimer's disease (AD) in China and its impact on global economic burden remain uncertain. 

Paper Mentions

Observational Patient Registry Clinical Trial
The aim of this study is to establish and perfect the China Cognition and Aging Study (China COAST) cohort, to clarify the epidemiology, influencing factors, genetic characteristics… Expand
ConditionsAlzheimer Disease, Late Onset, Familial Alzheimer Disease (FAD), Mild Cognitive Impairment(MCI), (+3 more)
Association between atherosclerosis and Alzheimer's disease: A systematic review and meta‐analysis
TLDR
A systematic review and meta‐analysis was conducted to study the difference of carotid intima–media thickness (CIMT) and the prevalence of atherosclerosis between AD patients and non‐AD controls. Expand
Recent advances in research on Alzheimer's disease in China
TLDR
Findings highlight the need for a brain health action plan to prevent and control AD and to reduce its increasing prevalence and dementia-related costs in China. Expand
Cost Effectiveness Analysis of Alzheimer's Disease
TLDR
Early and moderate-stage treatment of AD is cost-effective compared to severestage treatment, and the social and economic costs increased and the quality of life of the patients decreased in the progress stages of AD. Expand
Associated Factors of Total Costs of Alzheimer's Disease: A Cluster-Randomized Observational Study in China.
TLDR
In China, AD severity and comorbidities were the most critical factors impacting the total cost, and Optimizing care patterns, delaying disease progression, and managing comorebidities comprehensively could decrease the heavy burden of AD. Expand
The efficacy of statins in the treatment of Alzheimer’s disease: a meta-analysis of randomized controlled trial
TLDR
Investigation of the effect of statins in the treatment of Alzheimer’s disease found that statins could slow the deterioration of neuropsychiatric status and significantly improve activities of daily living ability in AD patients, but statins did not show an advantage in the change of the ADAS-Cog scale scores. Expand
The Economic Burden of Alzheimer's Disease in Zhejiang Province.
TLDR
The economic burden of AD in Zhejiang Province is heavy, similar to the national burden, and interventions based on demographic characteristics and disease severity can help reduce it. Expand
Major Cost Drivers in Assessing the Economic Burden of Alzheimer’s Disease: A Structured, Rapid Review
TLDR
The contribution of healthcare costs to the overall burden of Alzheimer’s Disease was not negligible; but was generally exceeded by social and informal care costs. Expand
Estimating Life Expectancy and Lifetime Healthcare Costs for Alzheimer's Disease in Taiwan: Does the Age of Disease Onset Matter?
TLDR
This study estimates LE, expected years of life lost (EYLL), and lifetime healthcare costs for Alzheimer's disease (AD) in Taiwan stratified by onset age and gender, using a method which integrates the product of the survival function and the mean cost function over a lifetime horizon. Expand
Report from the First Clinical Trials on Alzheimer’s Disease (CTAD) Asia-China 2018 : Bringing together Global Leaders
TLDR
The first CTAD Asia-China conference was held in China to bring together Western and Asian leaders in AD, and focused largely on how to develop successful trials in China, utilizing past experiences from the West. Expand
PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease
  • L. Jia, Yue Fu, +20 authors J. Jia
  • Medicine, Biology
  • Alzheimer's & dementia : the journal of the Alzheimer's Association
  • 2020
TLDR
The PSENs/APP mutation distribution in Chinese patients with familial Alzheimer's disease (FAD) remains unclear and the genetic features of Chinese FAD pedigrees with and without PSENa mutations are analyzed. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Determinants of societal costs in Alzheimer's disease: GERAS study baseline results
TLDR
To identify the main factors associated with societal costs of Alzheimer's disease (AD) in community‐dwelling patients across three European countries, a large number of patients from low-income backgrounds were selected. Expand
The worldwide costs of dementia 2015 and comparisons with 2010
In 2010, Alzheimer's Disease International presented estimates of the global cost of illness (COI) of dementia. Since then, new studies have been conducted, and the number of people with dementia hasExpand
The worldwide economic impact of dementia 2010
To acquire an understanding of the societal costs of dementia and how they affect families, health and social care services, and governments to improve the lives of people with dementia and theirExpand
The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode project
Care for demented people is very resource demanding, the prevalence is increasing and there is so far no cure.
Predictors of costs of care in Alzheimer’s disease: A multinational sample of 1222 patients
TLDR
This work aimed to identify what measures of disease severity are the most important predictors of societal costs of care and whether their relationship differs across countries. Expand
The prevalence of dementia in urban and rural areas of China
TLDR
The goal of this study was to estimate the changes in the prevalence of dementia, Alzheimer's disease (AD), and vascular dementia (VaD) among elderly Chinese individuals and to analyze differences between urban and rural areas. Expand
Economic impact of dementia in developing countries: an evaluation of Alzheimer-type dementia in Shanghai, China.
TLDR
Assessment of the economic cost of Alzheimer's disease in Shanghai, China found total cost was significantly associated with the degree of severity including cognitive function (MMSE) and activity of daily living (ADL). Expand
Cross sectional observational study on the societal costs of Alzheimer's disease.
TLDR
The societal costs of AD are very high, especially for patients with moderate and severe AD, which implies that treatments with the ability to delay progression of the disease into more severe stages have the potential to save large costs for society. Expand
Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina
TLDR
With the projected increase in the number of persons at risk for developing AD in emerging countries, the family cost of the disease will be significant and should be a matter of analysis when health policies are being designed in developing countries. Expand
Monetary costs of Alzheimer’s disease in China: protocol for a cluster-randomised observational study
TLDR
This is the first large-scale cluster-randomized observational study to estimate the economic burden of AD in Chinese patients and the methodology used was based on China’s current healthcare system and is suitable for the purpose of the study. Expand
...
1
2
3
4
5
...